Brow Lift in Topeka Kansas
Brow Lift in Topeka section, includes general infrmation about Brow Lift Procedure, Brow Lift Topeka Local News, Brow Lift Topeka Surgeon Locator and other Brow Lift related material.
Topeka Brow Lift - The Procedure
With age the brows drop below the eye line and wrinkles appear on the forehead, those make us look angry, sad and tired all times. Brow lift is most popular among ages 40-60 and you can combine it with a facelift or eyelid surgery.
Using the classic technique, the surgeon cuts ear to ear through the scalp behind the hairline. This allows him to get access to the forehead, release the muscles, removes extra skin and lift the eyebrows to higher position. This method is modified for people with high forehead and retreat in the hairline. Then the cut is made in front of the hairline so that brow lift doesn't cause additional retreat.
In the endoscopic approach 3-5 small incisions made on the scalp from ear to ear behind the hairline. Then using special tool extra skin and tissue being removed from the forehead and sometimes attached to the scalp from the inside. With time the wrinkles disappear. Sometimes the surgeon inserts special hook through the endoscop which attaches the tissue to the desired location. The hooks melt with time and the forehead reshapes. In another technique smaller cut is made through the temple areas, the extra skin is removed as described. This approach used when the outer portion of the brows needs to be lift. The operation can be done using local anesthetics with deep sedation.
Topeka Brow Lift - Risks
Every operation has its complications. This one includes damage to the forehead nerves that will result in inability to move the forehead or brows. Lost sensation, usually temporarily, around the scar. Hair loss in the scar margins and wider scar. Infection and bleeding. Endoscopic complications can force the surgeon to do the open surgery, which has longer recovery period.
Topeka Brow Lift - After Surgery
After the surgery with classic approach there might be uncomfortable felling of ant crawling and pain around the scar. Those usually disappear with time and the pain can be managed with painkillers. It may be difficult to open the eyes due to eyelid swallowing. The endoscopic approach has less pain and alter sensation.
Topeka Brow Lift - Healing
You can return to work 10-14 days after the surgery but the final results can be seen only after a few weeks. You must avoid vigorous activities that can elevate your blood pressure for a few weeks. Also avoid prolonged heat or sun exposure. Most marks of the surgery resolve after 3 weeks, minimal swallowing and small hemorrhages can be covered with make up.
More Topeka info...
Plastic Surgery News...
- Part of a large North American clinical trial comparing aggressive with less aggressive blood sugar treatment of diabetes and cardiovascular disease in adults with type 2 diabetes has stopped 18 months early because the more aggressive treatment increased risk of death. The less aggressive treatment arm of the study has not been stopped and is likely to complete its full term.
- According to research published in the Journal of the American Medical Association, there were no significant differences in clinical outcomes between patients receiving sirolimus- and paclitaxel-eluting stents in everyday clinical practice.
Researchers evaluated sirolimus- and paclitaxel-eluting stents for the prevention of symptom-driven clinical end points, using a study design reflecting everyday clinical practice. The SORT OUT II trial involved 2098 patients treated with percutaneous coronary intervention (PCI) and randomised to receive either sirolimus-eluting (n = 1065) or paclitaxel-eluting (n = 1033) stents. Indications for PCI included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina. Additionally, dual antiplatelet therapy with aspirin and clopidogrel was recommended for 1 year for all patients. After that period, clopidogrel was discontinued and aspirin continued lifelong, if tolerated.
The primary end point was a composite clinical end point of major adverse cardiac events, defined as either cardiac death, acute myocardial infarction, target lesion revascularisation, or target vessel revascularisation. Secondary end points were individual components of the composite end point, all-cause mortality and stent thrombosis.
The following results were reported:
• With respect to the primary end point, the sirolimus- and the paclitaxel-eluting stent groups did not differ significantly in major adverse cardiac events (98 [9.3%] vs. 114 [11.2%]; hazard ratio, 0.83 [95% confidence interval, 0.63-1.08]; P = 0.16)
• Additionally, no statistically significant differences were reported in stent thrombosis rates, rates of acute myocardial infarction, target lesion or vessel revascularisation, cardiac death or all-cause death
In a related editorial, the authors comment on possible limitations of the study:
1. The study randomised less than a third of the potentially eligible patients, which suggests that the cohort may not be as unselected as the authors had intended for emulating real life practice
2. The study was underpowered due to the small sample size coupled with relatively low event rates